Oncology

Back to articles

Role of 5-alpha reductase inhibitors for prostate cancer chemoprevention

KEY POINT

New evidence-based guidelines conclude that use of a 5-alpha reductase inhibitor (finasteride) for 7 years, in conjunction with periodic screening for prostate cancer, reduces the period prevalence of prostate cancer by approximately 26%.